- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:48 | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 39 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
| Fr | Immunovia initiates search for a new CFO | 3 | Seeking Alpha | ||
| Fr | IMMUNOVIA AB: Immunovia initiates search for a new CFO to support commercialization in the USA | 3 | Cision News | ||
| Fr | IMMUNOVIA AB: Invitation to Immunovia's Q4 presentation | 2 | Cision News | ||
| 31.01. | Change in number of shares and votes in Immunovia AB (publ) | 194 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen | |
| 20.01. | Immunovia AB announces outcome of exercise of warrants series TO 2 | 282 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 08.01. | Immunovia AB (Publ) presents Nomination Committee | 188 | PR Newswire | LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.... ► Artikel lesen | |
| 02.01. | The exercise period for warrants of series TO 2 beings today: Immunovia AB | 279 | PR Newswire | LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2... ► Artikel lesen | |
| 02.01. | IMMUNOVIA AB: The exercise period for warrants of series TO 2 beings today | 2 | Cision News | ||
| 28.12.24 | Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | 701 | PR Newswire | LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been... ► Artikel lesen | |
| 20.12.24 | IMMUNOVIA AB: Immunovia discovery study published in top protein research journal | 9 | Cision News | ||
| 19.12.24 | Immunovia AB: End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding | 126 | PR Newswire | LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities... ► Artikel lesen | |
| 18.12.24 | IMMUNOVIA AB: Immunovia CEO and board members announce intention to fully exercise their TO2 warrants | 1 | Cision News | ||
| 16.12.24 | IMMUNOVIA AB: Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test | 1 | Cision News | ||
| 11.12.24 | IMMUNOVIA AB: Immunovia announces financial calendar for financial year 2025/2026 | 3 | Cision News | ||
| 09.12.24 | Immunovia AB: Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer | 106 | PR Newswire | LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the... ► Artikel lesen | |
| 28.11.24 | IMMUNOVIA AB: Immunovia to present at the Redeye Technology & Life Science Day | 2 | Cision News | ||
| 27.11.24 | Immunovia AB: Immunovia Publishes Interim Report for January-September 2024 | 264 | PR Newswire | LUND, Sweden, Nov. 27, 2024 /PRNewswire/ --
July-September 2024
Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488).Net earnings amounted to -51.1... ► Artikel lesen | |
| 15.11.24 | IMMUNOVIA AB: Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas-Inherited Gastrointestinal Cancers | 3 | Cision News | ||
| 12.11.24 | Immunovia AB: Invitation to Immunovia's Q3 presentation | 208 | PR Newswire | LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 10,498 | -3,51 % | Teladoc Health (NYSE:TDOC) Sees Strong Trading Volume Following Analyst Upgrade | ||
| HIMS & HERS HEALTH | 35,060 | -28,52 % | Erhebliches Korrekturpotenzial: Highflyer Hims & Hers: Morgan Stanley senkt nach +500 Prozent den Daumen! | © Foto: Sina Schuldt - picture allianceDie Aktie der Online-Apotheke Hims & Hers hat in den vergangenen Wochen stark an Wert gewonnen. Jetzt hat US-Investmentbank Morgan Stanley die Anteile zurückgestuft.Der... ► Artikel lesen | |
| BECTON DICKINSON | 220,40 | +0,09 % | BD Recalls ChloraPrep Clear 1 ML Applicators | WASHINGTON (dpa-AFX) - Medical technology company Becton, Dickinson and Co. or BD has recalled one lot of ChloraPrep Clear 1 mL Applicators citing potential fungal contamination, the U.S. Food... ► Artikel lesen | |
| DEXCOM | 85,59 | -1,33 % | DexCom Inc. Q4 Income Falls | WASHINGTON (dpa-AFX) - DexCom Inc. (DXCM) released a profit for fourth quarter that decreased from last yearThe company's bottom line totaled $151.7 million, or $0.38 per share. This compares... ► Artikel lesen | |
| INVITAE | - | - | Invitae Aktie: Drastischer Kursverfall trotz Umsatzwachstum | Der Aktienkurs des Biotechnologieunternehmens Invitae ist in den letzten Tagen stark eingebrochen. Am 8. September fiel der Kurs um 25% auf 0,0003 USD, was einen besorgniserregenden Trend fortsetzt.... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,732 | -2,40 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,660 | -27,83 % | XFRA RH7: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILRYMAN HEALTHCARE... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results | Revenues increased 14% for the quarter compared to prior year and 13% year-to-datePositive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024Year-to-date net loss... ► Artikel lesen | |
| CYTOSORBENTS | 1,060 | +1,73 % | CytoSorbents sichert sich 1,6 Millionen US-Dollar durch Optionsscheinausübungen | ||
| TEMPEST THERAPEUTICS | 0,822 | -1,50 % | Tempest Therapeutics: Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma | Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif.... ► Artikel lesen | |
| ONTRAK | 1,610 | 0,00 % | Ontrak Health Announces 2024 Third Quarter Financial Results | MIAMI--(BUSINESS WIRE)--Ontrak, Inc. (NASDAQ: OTRK) ("Ontrak" or the "Company"), a leading AI-powered and technology-enabled behavioral healthcare company, today reported its financial results... ► Artikel lesen | |
| SENSEONICS | 0,870 | -1,07 % | Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting | GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable... ► Artikel lesen | |
| STAAR SURGICAL | 15,340 | -1,06 % | STAAR SURGICAL CO - 10-K, Annual Report | ||
| PATTERSON COMPANIES | 29,600 | -0,67 % | Patterson Companies Announces Expiration of "Go-Shop" Period | ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Companies, Inc. (Nasdaq: PDCO), a leading dental and animal health distributor, today announced the expiration of the 40-day "go-shop" period under the... ► Artikel lesen |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+2,91 %) liegt der Kurs bei 0,018 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.
